Fig. 1: Selected ligands of mGlu receptor subtypes. | npj Parkinson's Disease

Fig. 1: Selected ligands of mGlu receptor subtypes.

From: Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease

Fig. 1

Mavoglurant, dipraglurant, and foliglurax have been clinically developed for the treatment of PD; basimglurant has been clinically developed for the treatment of major depressive disorder (see text). NAM negative allosteric modulator, PAM positive allosteric modulator. Chemical names are detailed in the text.

Back to article page